RVPH (MKap $73 M) Die nächste AXSM ? (Seite 63)
eröffnet am 29.01.21 18:41:28 von
neuester Beitrag 07.06.24 15:19:18 von
neuester Beitrag 07.06.24 15:19:18 von
Beiträge: 798
ID: 1.340.543
ID: 1.340.543
Aufrufe heute: 3
Gesamt: 75.923
Gesamt: 75.923
Aktive User: 0
ISIN: US76152G1004 · WKN: A2QK7Q · Symbol: RVPH
1,4400
USD
0,00 %
0,0000 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
| TitelBeiträge |
|---|
29.05.24 · globenewswire  |
28.05.24 · globenewswire |
21.05.24 · globenewswire |
15.05.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2000 | +25,71 | |
| 2,7700 | +21,49 | |
| 43,31 | +16,99 | |
| 36,15 | +16,28 | |
| 3,8600 | +16,27 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 17,670 | -19,68 | |
| 35,00 | -20,45 | |
| 5,3600 | -27,07 | |
| 0,5150 | -31,33 | |
| 1,0200 | -71,67 |
Beitrag zu dieser Diskussion schreiben
Feedback
Übersetzung aus dem Link mit Deepl Translator:
…..sehr interessant 🧐 ist folgendes:
To further explore this therapeutic potential, we intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.
Um dieses therapeutische Potenzial weiter zu erforschen, beabsichtigen wir, im Jahr 2024 einen Antrag auf Zulassung eines neuen Arzneimittels (IND) für Brilaroxazin-Lipogel bei Psoriasis einzureichen.🚀
…..sehr interessant 🧐 ist folgendes:
To further explore this therapeutic potential, we intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.
Um dieses therapeutische Potenzial weiter zu erforschen, beabsichtigen wir, im Jahr 2024 einen Antrag auf Zulassung eines neuen Arzneimittels (IND) für Brilaroxazin-Lipogel bei Psoriasis einzureichen.🚀
News!!!
Ein Auszug:
CUPERTINO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan, May 10-13, 2023. The ISID poster is available at revivapharma.com/publications.
“The multifaceted activity of brilaroxazine offers the promise to improve the quality of life and provide a novel treatment option for patients with psoriasis, an inflammatory condition stemming from serotonin and dopamine dysfunction,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “We were excited to present encouraging preclinical data at ISID 2023 highlighting the therapeutic potential of brilaroxazine lipogel, a novel, proprietary lipogel formulation for the topical treatment of psoriasis. We have filed a composition of matter patent for brilaroxazine-lipogel and a separate patent for its use in psoriasis. Mental illness, including schizophrenia and depression, is a major comorbidity in patients with psoriasis. Brilaroxazine has established a well-tolerated safety profile with robust efficacy in about 300 patients with schizophrenia from Phase 1B and Phase 2 studies. To further explore this therapeutic potential, we intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.”
Psoriasis is a chronic dermal inflammatory disease with a global prevalence of ~125 million. Dopamine (D) and serotonin (5-HT) signaling pathways play an important role in the pathobiology of psoriasis, and lead to increased inflammatory mediators (TNF-α, IFN-γ, IL-1β, IL-6, IL-8), keratinocyte activation and deterioration, and worsening symptoms. Current treatments include multiple modalities but are limited by long-term side effects (topicals), toxicities (orals) or risk of immunogenicity, serious infection, and malignancy (biologics). Brilaroxazine (RP5063) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology. Preclinical studies in the imiquimod-induced psoriatic mouse model (BALB/c) were used to evaluate the potential of topical liposomal-gel formulation of brilaroxazine for the treatment of psoriasis.
Key poster highlights support the therapeutic potential of brilaroxazine lipogel in psoriasis:
Brilaroxazine lipogel treatment group compared to imiquimod-induced psoriatic group:
Consistently and significantly lowered Psoriasis Area and Severity Index (PASI) scores on Days 3-12 (P=0.03), with maximum difference on Days 11-12
Significantly lowered Baker’s score (P=0.003)
Significantly lowered serum biomarkers Ki-67 (P=0.001) and TGF-β (P=0.008)
Provides initial proof-of-concept (PoC) for the brilaroxazine topical liposomal-gel formulation
Supports D and 5-HT receptors as viable psoriasis targets and offers an initial glimpse at changes indicating anti-inflammatory, anti-fibrotic, and anti-proliferative effects
Brilaroxazine formulation with the lipogel delivery system offers a potential option for psoriasis, which has links to mental illness (as high as 36%)
https://www.stocktitan.net/news/RVPH/reviva-pharmaceuticals-…
Ein Auszug:
CUPERTINO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology (ISID) Meeting in Tokyo, Japan, May 10-13, 2023. The ISID poster is available at revivapharma.com/publications.
“The multifaceted activity of brilaroxazine offers the promise to improve the quality of life and provide a novel treatment option for patients with psoriasis, an inflammatory condition stemming from serotonin and dopamine dysfunction,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “We were excited to present encouraging preclinical data at ISID 2023 highlighting the therapeutic potential of brilaroxazine lipogel, a novel, proprietary lipogel formulation for the topical treatment of psoriasis. We have filed a composition of matter patent for brilaroxazine-lipogel and a separate patent for its use in psoriasis. Mental illness, including schizophrenia and depression, is a major comorbidity in patients with psoriasis. Brilaroxazine has established a well-tolerated safety profile with robust efficacy in about 300 patients with schizophrenia from Phase 1B and Phase 2 studies. To further explore this therapeutic potential, we intend to submit an investigational new drug application (IND) for brilaroxazine lipogel in psoriasis in 2024.”
Psoriasis is a chronic dermal inflammatory disease with a global prevalence of ~125 million. Dopamine (D) and serotonin (5-HT) signaling pathways play an important role in the pathobiology of psoriasis, and lead to increased inflammatory mediators (TNF-α, IFN-γ, IL-1β, IL-6, IL-8), keratinocyte activation and deterioration, and worsening symptoms. Current treatments include multiple modalities but are limited by long-term side effects (topicals), toxicities (orals) or risk of immunogenicity, serious infection, and malignancy (biologics). Brilaroxazine (RP5063) is a modulator of D and 5-HT receptors with multifaceted activity that may affect underlying psoriasis pathology. Preclinical studies in the imiquimod-induced psoriatic mouse model (BALB/c) were used to evaluate the potential of topical liposomal-gel formulation of brilaroxazine for the treatment of psoriasis.
Key poster highlights support the therapeutic potential of brilaroxazine lipogel in psoriasis:
Brilaroxazine lipogel treatment group compared to imiquimod-induced psoriatic group:
Consistently and significantly lowered Psoriasis Area and Severity Index (PASI) scores on Days 3-12 (P=0.03), with maximum difference on Days 11-12
Significantly lowered Baker’s score (P=0.003)
Significantly lowered serum biomarkers Ki-67 (P=0.001) and TGF-β (P=0.008)
Provides initial proof-of-concept (PoC) for the brilaroxazine topical liposomal-gel formulation
Supports D and 5-HT receptors as viable psoriasis targets and offers an initial glimpse at changes indicating anti-inflammatory, anti-fibrotic, and anti-proliferative effects
Brilaroxazine formulation with the lipogel delivery system offers a potential option for psoriasis, which has links to mental illness (as high as 36%)
https://www.stocktitan.net/news/RVPH/reviva-pharmaceuticals-…
Die Aufmerksamkeit steigt Woche für Woche. Es stehen bis Ende Mai mehrere Events an. Lax hatte ja vor dem Readout Phase 3, fortlaufende News angekündigt. Könnte es vorab schon um JV Partner gehen oder ist es nach dem Readout wahrscheinlicher…..Mal schauen 👀 Immerhin müssen im Vorfeld die Fäden gezogen werden, denn nach positiven P 3 News gibt es bestimmt kein Halten mehr!
Nur meine persönliche Meinung und keine Handlungsempfehlung.
Nur meine persönliche Meinung und keine Handlungsempfehlung.
Antwort auf Beitrag Nr.: 73.812.229 von Univego am 09.05.23 09:05:46Die Konferenz in Tokio könnte genutzt werden, um einen Partner zu finden, ich denke das macht auf jeden Fall Sinn. Lassen wir uns überraschen.
Zitat von Univego: Die folgenden Meetings stehen zeitnah an….
Am Freitag geht es zuerst um Brilaroxazine und die Wirksamkeit bei Psoriasis auf einem Dermatologen Congress in Tokio!
International Societies for Investigative Dermatology (ISID) Meeting 2023
Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced psoriatic BALB/c mouse model
Date: May 12, 2023
Time: 6:10 – 7:40pm JST
Presenters: Laxminarayan Bhat
Location: Keio Plaza Hotel, Tokyo, Japan
American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023
Poster Presentation: CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokinetic
Date: Friday, May 19, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
Poster Presentation: Single-dose Brilaroxazine Pharmacokinetics, Metabolism, and Excretion Profile in Animals and Humans
Date: Saturday, May 20, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
American Thoracic Society (ATS) 2023
Poster Presentation: Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary Fibrosis
Date: Wednesday, May 24, 2023
Time: 8:00-10:00am ET
Presenters: Laxminarayan Bhat
Location: Walter E. Washington Convention Center, Washington, DC, USA
https://www.stocktitan.net/news/RVPH/reviva-pharmaceuticals-…
Trading Spotlight
yahoo.finance: adams
vor 53 Minuten
Ich habe mir gerade die Fintel-Daten für RVPH angesehen. Ich bin mir nicht sicher, ob dies bereits erwähnt wurde, aber es sieht so aus, als ob CEO Lax einen 13D/A eingereicht hat und nun 13,5% der Anteile besitzt. Dieses Board wurde in letzter Zeit überflutet, so dass ich vielleicht verpasst haben, diese diskutiert werden.
https://de.advfn.com/borse/NASDAQ/RVPH/nachrichten/90979683/…
vor 53 Minuten
Ich habe mir gerade die Fintel-Daten für RVPH angesehen. Ich bin mir nicht sicher, ob dies bereits erwähnt wurde, aber es sieht so aus, als ob CEO Lax einen 13D/A eingereicht hat und nun 13,5% der Anteile besitzt. Dieses Board wurde in letzter Zeit überflutet, so dass ich vielleicht verpasst haben, diese diskutiert werden.
https://de.advfn.com/borse/NASDAQ/RVPH/nachrichten/90979683/…
Die folgenden Meetings stehen zeitnah an….
Am Freitag geht es zuerst um Brilaroxazine und die Wirksamkeit bei Psoriasis auf einem Dermatologen Congress in Tokio!
International Societies for Investigative Dermatology (ISID) Meeting 2023
Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced psoriatic BALB/c mouse model
Date: May 12, 2023
Time: 6:10 – 7:40pm JST
Presenters: Laxminarayan Bhat
Location: Keio Plaza Hotel, Tokyo, Japan
American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023
Poster Presentation: CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokinetic
Date: Friday, May 19, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
Poster Presentation: Single-dose Brilaroxazine Pharmacokinetics, Metabolism, and Excretion Profile in Animals and Humans
Date: Saturday, May 20, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
American Thoracic Society (ATS) 2023
Poster Presentation: Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary Fibrosis
Date: Wednesday, May 24, 2023
Time: 8:00-10:00am ET
Presenters: Laxminarayan Bhat
Location: Walter E. Washington Convention Center, Washington, DC, USA
https://www.stocktitan.net/news/RVPH/reviva-pharmaceuticals-…
Am Freitag geht es zuerst um Brilaroxazine und die Wirksamkeit bei Psoriasis auf einem Dermatologen Congress in Tokio!
International Societies for Investigative Dermatology (ISID) Meeting 2023
Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced psoriatic BALB/c mouse model
Date: May 12, 2023
Time: 6:10 – 7:40pm JST
Presenters: Laxminarayan Bhat
Location: Keio Plaza Hotel, Tokyo, Japan
American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023
Poster Presentation: CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokinetic
Date: Friday, May 19, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
Poster Presentation: Single-dose Brilaroxazine Pharmacokinetics, Metabolism, and Excretion Profile in Animals and Humans
Date: Saturday, May 20, 2023
Time: 5:00-7:00pm ET
Presenters: Laxminarayan Bhat
Location: St. Louis Union Station Hotel, St. Louis, MA, USA
American Thoracic Society (ATS) 2023
Poster Presentation: Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary Fibrosis
Date: Wednesday, May 24, 2023
Time: 8:00-10:00am ET
Presenters: Laxminarayan Bhat
Location: Walter E. Washington Convention Center, Washington, DC, USA
https://www.stocktitan.net/news/RVPH/reviva-pharmaceuticals-…
Das Volumen heute 69.388 Stk. Ist ziemlich unteriedisch
Link zur letzten Präsentation des KOL Webinar:
https://revivapharma.com/wp-content/uploads/2023/05/2023-Rev…
https://revivapharma.com/wp-content/uploads/2023/05/2023-Rev…
Durchsuchen
RVPH (MKap $73 M) Die nächste AXSM ?
